Filtered By:
Cancer: Prostate Cancer
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 121 results found since Jan 2013.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
Rhabdomyolysis-induced acute kidney injury after administration of a red yeast rice supplement: A case report
CONCLUSION: We speculate that statins, the main lipid-lowering component of RYR, or a combination of statins and abiraterone, will increase the risk of rhabdomyolysis.PMID:37637685 | PMC:PMC10450378 | DOI:10.12998/wjcc.v11.i23.5547
Source: Clinical Prostate Cancer - August 28, 2023 Category: Cancer & Oncology Authors: Ya-Han Wang Si-Shuo Zhang Hai-Tao Li Hong-Wei Zhi Hong-Yun Wu Source Type: research
PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal
CONCLUSION: We conclude that this regimen deserves to be preclinically evaluated because of its clinical potential for the treatment of prostate cancer.PMID:37287286 | DOI:10.2174/0929867330666230607104441
Source: Current Medicinal Chemistry - June 8, 2023 Category: Chemistry Authors: Adriana Romo-Perez Guadalupe Dom ínguez-Gómez Alma Ch ávez-Blanco Aurora Gonz ález-Fierro Jos é Correa-Basurto Alfonso Due ñas-González Source Type: research
Retraction Note: Fluvastatin-Loaded Emulsomes Exhibit Improved Cytotoxic and Apoptosis in Prostate Cancer Cells
AAPS PharmSciTech. 2023 Jun 2;24(5):128. doi: 10.1208/s12249-023-02591-y.NO ABSTRACTPMID:37266798 | DOI:10.1208/s12249-023-02591-y
Source: AAPS PharmSciTech - June 2, 2023 Category: Drugs & Pharmacology Authors: Nabil A Alhakamy Shaimaa M Badr-Eldin Hibah M Aldawsari Anas Alfarsi Thikryat Neamatallah Solomon Z Okbazghi Usama A Fahmy Osama A A Ahmad Basma G Eid Wael Ali Mahdi Adel F Alghaith Sultan Alshehri Shadab Md Source Type: research
Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study
CONCLUSIONS: These findings may improve the understanding of lipid metabolism in prostate carcinogenesis by disease aggressiveness, and by race while emphasizing the importance of cholesterol control.PMID:37154584 | DOI:10.1002/pros.24546
Source: Cancer Control - May 8, 2023 Category: Cancer & Oncology Authors: Michael T Marrone Anna E Prizment David Couper Kenneth R Butler Brad C Astor Corinne E Joshu Elizabeth A Platz Alison M Mondul Source Type: research
Association Between Statin Exposure and Incidence and Prognosis of Prostate Cancer: A Meta-analysis Based on Observational Studies
This study aimed to investigate the effect of statin exposure on PCA incidence and prognosis. PubMed, Web of Science, Embase, and Cochrane databases were searched for observational studies on the association between statin exposure and PCA from inception until July 2022. The primary endpoints were the incidence of PCA and the survival rate. A total of 21 studies were included in this meta-analysis. The pooled estimates showed that exposure to hydrophilic statins was not associated with the incidence of PCA (odds ratio [OR]=0.94, 95% CI=0.88-1.01, P=0.075), while the incidence of PCA was significantly decreased in populatio...
Source: Clinical Prostate Cancer - May 5, 2023 Category: Cancer & Oncology Authors: Zipei Cao Jie Yao Yujing He Dandi Lou Jianing Huang Yeyuan Zhang Meiling Chen Zhizhen Zhou Xiaomei Zhou Source Type: research
